Immuno-Oncology

Many oncology practices are learning lessons about the importance of persistence, persuasion, and creativity in getting I/O drugs to the patients who need them.

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.

Tony Mok, MD, professor, Department of Clinical Oncology, Chinese University of Hong Kong, discusses updated data with pembrolizumab in patients with non–small cell lung cancer.

Marina Chiara Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses patient reported outcomes with durvalumab by PD-L1 expression in patients with stage III unresectable non–small cell lung cancer.

Eric Jonasch, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the use of single-agent pembrolizumab in the treatment of patients with metastatic non–clear cell renal cell carcinoma.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

The FDA has approved pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.

During an OncLive Peer Exchange® discussion, moderator Mark A. Socinski, MD, and other lung cancer experts from across the United States discuss what, in this context, the PACIFIC trial results mean for practicing oncologists and their patients.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the improved outlook for patients with metastatic bladder cancer.

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

The FDA has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.